^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ID-LV305

    i
    Associations
    News

    Trials

    Company:
    Merck (MSD)
    Drug class:
    Immunostimulant, NY ESO 1 inhibitor, Dendritic cell activator
    Related drugs:
    Associations
    News

    Trials

    Apply
    Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (NCI-2018-00926) (NCT03450122)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/16/2023
    Initiation :
    09/13/2018
    Primary completion :
    12/06/2022
    Completion :
    12/06/2022
    HLA-A • CTAG1B
    |
    cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305
    Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (NCT02122861)
    Phase 1
    Immune Design
    Completed
    Last update posted :
    03/06/2019
    Initiation :
    05/30/2014
    Primary completion :
    11/14/2018
    Completion :
    12/15/2018
    CTAG1B
    |
    CTAG1B expression
    |
    Keytruda (pembrolizumab) • ID-LV305